Masterclass: How to Approach AML in PG Exams: The High-Yield Checklist

draditikumar
May 24
3 min read

If you are preparing for NEET PG, INI-CET, or FMGE, you already know that examiners love Acute Myeloid Leukemia (AML). It is one of those classic "rank-breaking" topics.

Why? Because a modern exam question won’t just ask you to spot a blast under a microscope. Today’s clinical stems tightly integrate morphology, cytochemistry, immunophenotyping (flow cytometry), and cytogenetics.

When a long, intimidating case description pops up on your screen, it is easy to panic and get lost in the numbers. To prevent that, you need a flawless mental algorithm. Use this exact 3-Step Checklist to systematically break down any AML question and secure your marks.

Step 1: Establish the Baseline (Morphology & Cytochemistry)

Before diving into complex genetics, look for the foundational clues in the stem.

The Diagnostic Threshold

Traditionally, the diagnosis of AML requires more than or equal to 20% blasts in the bone marrow or peripheral blood. However, write this down in your high-yield notebook: Under current WHO/ICC guidelines, if the patient has the recurrent genetic translocations t(8;21), inv(16), or t(15;17), the 20% blast threshold is waived. The presence of these mutations is diagnostic of AML on its own.

Morphological & Chemical Clues

Look out for these classic exam "buzzwords":

Auer Rods: Clumped, needle-like azurophilic granules in the cytoplasm. If you see them, you are looking at a myeloid lineage.
Faggot Cells: Cells packed with bundles of multiple Auer rods. This is the ultimate pathognomonic clue for Acute Promyelocytic Leukemia (APML / AML-M3).

The Cytochemistry Cheat Sheet

If the question includes a lab report with special stains, memorize this trio:

Myeloperoxidase (MPO): Strongly positive in granulocytic differentiation (AML M1, M2, M3).
Non-Specific Esterase (NSE): Strongly positive in monocytic differentiation (AML M4, M5). Key detail: This reaction is inhibited by Sodium Fluoride.
Periodic Acid–Schiff (PAS): Exhibits a distinct block-like positivity in erythroid leukemia (AML M6).

Step 2: Decode the Flow Cytometry (Immunophenotyping) Markers

Examiners love throwing a string of "CD markers" at you to see if you can distinguish myeloid blasts from lymphoid blasts (ALL). Use this structured table to lock down the high-yield markers:

Marker Category / Subtype	Key Positive Markers	High-Yield Exam Context
Pan-Myeloid Baseline	CD13, CD33, CD117, MPO	The definitive proof that the leukemia is myeloid, not lymphoid.
Monocytic Subtypes (M4 / M5)	CD14, CD64, CD11b, CD36	Expect these markers in clinical stems describing a patient with gingival (gum) hypertrophy.
Megakaryocytic Subtype (M7)	CD41, CD61, CD42b	Highly associated with Down Syndrome patients under 3 years old.
Immature Stem Cell	CD34, HLA-DR	Crucial Exception: APML (M3) is characteristically negative for CD34 and HLA-DR!

Step 3: Map the Cytogenetics & Prognosis

This is where the highest-ranked students win their marks. You must know which translocations predict a good recovery versus a poor outcome.

🟢 Favorable (Good) Prognosis

t(8;21): Involves the RUNX1-RUNX1T1 fusion. Patients generally show an excellent response to standard chemotherapy.
inv(16) or t(16;16): Involves CBFB-MYH11. Look for a bone marrow description mentioning abnormal, atypical eosinophils with dark purple granules.
t(15;17): The PML-RARA fusion (APML). This is a medical emergency. These patients present with severe, life-threatening Disseminated Intravascular Coagulation (DIC) due to the release of procoagulants from the promyelocyte granules. Treatment must start immediately with All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide.

🔴 Adverse (Poor) Prognosis

Complex or Monosomal Karyotypes: Deletions of chromosome 5 (5q-) or chromosome 7 (-7). These are frequently seen in therapy-related AML or cases transforming out of Myelodysplastic Syndromes (MDS).
FLT3-ITD Mutation: Internal tandem duplications in the FLT3 gene predict highly aggressive disease and rapid relapse, though targeted FLT3 inhibitors are changing this landscape.

What topic in haematology trips you up the most? Let me know in the comments below, and we will break it down in the next blog post!